CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Liminal BioSciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Liminal BioSciences Inc
231 Dundas Street East
Phone: (450) 781-0115p:450 781-0115 BELLEVILLE, ON  K8N 1E2  Canada Fax: (450) 781-4477f:450 781-4477
This company ceased filing statements with the SEC on 10/6/2023.
On 9/26/2023, the Company was acquired by Structured Alpha LP
This company is no longer actively traded on any major stock exchange.
Business Summary
Liminal BioSciences Inc. is a Canada-based development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board AleksanderKrstajic 59 9/1/2020 9/1/2020
President PatrickSartore 49 11/13/2020 10/22/2007
Chief Executive Officer BrucePritchard 50 11/13/2020 10/22/2007
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Telesta Therapeutics Inc 2600 Alfred-Nobel Blvd Suite 301 SAINT-LAURENT QC Canada

Business Names
Business Name
Fairhaven Pharmaceuticals Inc.
Liminal BioSciences Holdings Limited
Liminal BioSciences Limited
6 additional Business Names available in full report.

General Information
Number of Employees: 43 (As of 12/31/2022)
Outstanding Shares: 3,249,534 (As of 8/4/2023)
Shareholders: 53
Stock Exchange: NASD
Fax Number: (450) 781-4477


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 26, 2024